ArticleCell death & disease2026
IRX1 suppresses breast cancer progression by inhibiting fatty acid de novo synthesis through downregulating ACACA expression.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Breast cancer remains a major threat to women's health and survival worldwide. Iroquois homeobox 1 (IRX1), a developmentally regulated transcription factor, acts as a tumor suppressor in several cancers. However, its mechanistic role in breast cancer remains elusive. In this study, we demonstrate that IRX1 is downregulated in breast cancer tissues and cell lines due to promoter hypermethylation. IRX1 functioned as a tumor suppressor both in vitro and in vivo. Mechanistically, IRX1 interacts with NME1 and promotes its nuclear localization. Subsequently, NME1 facilitates the transcriptional regulation of ACACA by IRX1. The IRX1-NME1 axis modulates de novo fatty acid synthesis and breast cancer progression by targeting ACACA. In conclusion, our findings reveal that the IRX1- NME1/ACACA axis plays a critical role in de novo fatty acid synthesis and breast cancer progression, providing new insights into gene regulatory interactions and highlighting its potential as a novel therapeutic target for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.